In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated.
One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, patients who experienced an immune-related adverse event had better overall survival, progression-free survival, objective response rate, and disease control rate compared with patients who did not have an immune-related adverse event. Patients who developed immune-related adverse events after 10 weeks of nivolumab treatment had better progression-free survival than those who developed immune-related adverse events earlier than 10 weeks.
This study provides valuable information about the association between the toxicity of immunotherapy and clinical outcomes for RCC patients taking nivolumab.